News

Daiichi Sankyo is developing Edoxaban for several other indications which include stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent venous thromboembolism. Further, Daiichi

Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx’s existing investors, will maintain its investment in ImpactRx. Under the terms of the acquisition

IMO-2125 is a novel immune modulator being developed as a component of treatment for chronic hepatitis C virus (HCV) infection. IMO-2125 has been evaluated in 96 HCV-infected patients

The vaccines division of the Sanofi-aventis Group, Sanofi Pasteur said the FDA’s decision was supported by the results from one Phase II and three Phase III multicenter trials,

InfoGard is approved by the Office of the National Coordinator for Health Information Technology (ONC) of the US Department of Health and Human Services (HHS) as an Authorized

Japanese approval was given on the basis a pivotal Phase III Embrace (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) study results and a Phase II

To better understand this mechanism, the research group focused on the signaling of the extracellular signal-regulated kinases (ERK), intracellular signaling molecules known to play an important role in

Lipacreon is indicated as a treatment for pancreatic exocrine insufficiency (PEI) due to chronic pancreatitis, pancreatectomy, cystic fibrosis and other conditions. Lipacreon contains pancreatic enzymes such as amylase,

Baxter‘s net income was $570m for the first quarter 2011, or $0.98 per diluted share, compared to net income of $63m, or $0.11 per diluted share, for the